Medable continues stake in DCT solution space
The strategic partnership between biopharmaceutical solutions organization Syneos Health and technology platform Medable focuses on patient-centered clinical trials, reduction of site and patient burden, improve enrollment and retention, and increase patient access through decentralized clinical trial (DCT) solutions.
Medable and Syneos Health first partnered in April 2021 and have since collaborated on more than fifteen clinical trials across multiple therapeutic areas. Since the beginning of their partnership, Syneos Health and Medable, had adopted tools to create a scalable operational model for decentralized and hybrid studies.
Leigh Householder told Outsourcing-Pharma, when sharing her thoughts on the 2022 Health Trends: Insights for Industry Change Agents, that the clinical trial industry is one working toward “sustainable acceleration.”
“The pandemic forced fast-moving innovation, prompting biopharma organizations around the world to validate real-time insight and learnings that are now fueling industry change and value creation,” said Householder.
“The last two years have taught us that DCTs are here to stay,” said Dr. Michelle Longmire, co-founder and CEO of Medable, who shared her thoughts on direction of the industry field in 2021.
“Both Medable and Syneos Health envision a near future where every life sciences company has the tools they need to revolutionize human health by expanding access to clinical trials through the use of technology,” Longmire added.
Shortly after Longmire’s comments, Medable and CVS Health announced a partnership in 2022 to increase study access at MinuteClinic locations as a means of expanding access to clinical trials through company’s technology platform.
Medable and the DCT space
Medable is no stranger to the DCT world, and has had a focus on it since the beginning of 2020. The technology company committed to that focus when launching an eConsent solution, telehealth eCOA technology, and partnered with MRN.
Shortly after the original agreement to partner with Syenos, Medable’s chief scientific officer, Pamela Tenaerts, told us, “I passionately believe we need to change the current clinical trial infrastructure to better answer vital medical research questions in ways the current system cannot…”
In March 2022, Medable added Cognizant to its Medable Partner Network so Cognizant could leverage the technology company’s digital platform to streamline DCTs. At that time Maryanne Rizk, chief strategy office of Medable stated that the company is looking to grow its network of accredited partners who provide decentralized services.
Last month, Medable announced that its software as a service (SaaS) electronic management solution, Total Consent, was available at more than 120 locations worldwide.
